Monoclonal antibody (mAb) based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have improved patient survival across various tumor types 1-8. The gene discussed is CTLA4; the disease is neoplasm.